The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Treatment of Multiple Sclerosis: A Review
Open accessAbstract
Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of the central nervous system, and the leading cause of nontraumatic neurological disability in young adults. Effective management requires a multifaceted approach to control acute attacks, manage progressive worsening, and remediate bothersome or disabling symptoms associated with this illness. Remarkable advances in treatment of all forms of MS, and especially for relapsing disease, have favorably changed the long-term outlook for many patients. There also has been a conceptual shift in understanding the immune pathology of MS, away from a purely T-cell-mediated model to recognition that B cells have a key role in pathogenesis. The emergence of higher-efficacy drugs requiring less frequent administration have made these preferred options in terms of tolerability and adherence. Many experts now recommend use of these as first-line treatment for many patients with early disease, before permanent disability is evident.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It may also partly explain why immunosuppressive therapies have thus far had little or no effect on disability accumulation in progressive MS trials4.”
From Locus for severity implicates CNS resilience in progression of multiple sclerosis (2023) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“While disease-modifying therapies have significantly improved prognosis for relapsing forms of multiple sclerosis (RMS), effective treatments for the progressive, neurodegenerative phase are lacking.”
From Insights and challenges on animal models for progressive multiple sclerosis (2026) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Most DMTs are approved for treatment of relapsing MS (RMS) [17], a smaller number have shown benefit in some SPMS populations [19, 22, 23], but only one DMT has shown efficacy for treatment of PPMS, underlining the unmet need of treatment options for these patients [20] (Table 2).”
From Insights and challenges on animal models for progressive multiple sclerosis (2026) · cites this paper as [17]
In the citing paper
“For example, IFN-γ has been proposed to play both stimulatory and suppressive roles in cancer, and type I IFNs are used both as an immunosuppressant to treat multiple sclerosis and as immunostimulatory adjuvant treatments for cancer (for example melanoma) and chronic viral infection (for example HCV)48–50.”
From Causal identification of single-cell experimental perturbation effects with CINEMA-OT (2023) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30470-2 · Cited by 8,167
New Multiple Sclerosis Phenotypic Classification
LUBLIN, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,277
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdová, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., LUBLIN, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,433
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E. W., O'Connor, P. W., Polman, C. H., Hohlfeld, R., Calabresi, P. A., Selmaj, K. W., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,670
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. Μ., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,446
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationOral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comı, G., Hartung, H., Khatri, B. O., Montalbán, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,220
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,144
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Cited by
Sorted by citations
Items 601–700 of 966
Zhang, Q., Yan, S., Sun, D., Geng, Z., & Zhang, P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1134918 · Cited by 2
Vastrad, B. M., Pattanashetti, S., & Vastrad, C. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.05.570305 · Cited by 2
Department of Psychology, T. J. B., MirMoeini, P., Hosseini Bayazi, M., Department of Psychology, T. J. B., Khlatbari, J., & Department of Psychology, T. B. (2022) · Journal of Arak University of Medical Sciences · doi:10.32598/jams.25.1.6671.1 · Cited by 1
“ultiple sclerosis (MS) is a chronic disease of the central nervous system that affects the brain and spinal cord [1].”
BackgroundInsights and challenges on animal models for progressive multiple sclerosis
Nalepa, I. F., Haahr, N. O., Bekiaris, V., Jakobsen, M. R., Asuni, A. A., & Benmamar-Badel, A. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03805-3 · Cited by 1
“Although no curative treatment exists, numerous disease-modifying therapies (DMTs) have been approved [17, 18].”
Shiatsu-associated physical therapy on pain and fatigue on people with multiple sclerosis
Fillis, M. M. A., Nicio, R., Nicio, R. T., dos Santos, G. A., Brandet, J. M., & Ribeiro, H. G. G. (2022) · Fisioterapia em Movimento · doi:10.1590/fm.2022.35114 · Cited by 1
Beyond ocrelizumab in primary progressive multiple sclerosis
Williams, T. E., & Chataway, J. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00724-8 · Cited by 1
Azathioprine in the Treatment of Multiple Sclerosis: A Single Center Experience from Nepal
Rajbhandari, R., Shakya, S., Yadav, J. K., Tamrakar, A., Jaiswa, S. K., Rajbhandari, P., & Chandra, A. (2022) · Annapurna Journal of Health Sciences · doi:10.52910/ajhs.59 · Cited by 1
Associations between multiple sclerosis and in-hospital outcomes of patients with hemorrhagic stroke
Xu, W., Yan, D., & Ning, Z. (2023) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2023.107281 · Cited by 1
Multiple sclerosis and experimental autoimmune encephalomyelitis: A review
Cachuba, R. M., Scherrer, E. C., Ramos, K. A., Carli, A. D. P., de Castro, S. B. R., & Alves, C. C. D. S. (2023) · Seven Editora eBooks · doi:10.56238/uniknowindevolp-045 · Cited by 1
Data on Ocrelizumab Treatment Collected by MS Patients in Germany Using Brisa App
Papukchieva, S., Kahn, M., Eberl, M., Friedrich, B., Joschko, N., & Ziemssen, T. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14040409 · Cited by 1
“While progress has been made in terms of developing new treatments due to a more comprehensive understanding of the course and pathogenesis of MS [14], MS is still considered to be an incurable disease [4].”
BackgroundMultiple sclerosis is at a checkpoint: advancing the program
Smith, B. C., & Williams, J. L. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-02094 · Cited by 1
“Patients with MS experience sensory and motor function loss due to myelin and/or axon damage perpetuated by infiltrating immune cells (Hauser and Cree, 2020).”
BackgroundInfluentialSexual Health Education and Quality of Counseling in Pediatric-Onset Multiple Sclerosis
Burk, K. C., Pagarkar, D., Khoshnood, M. M., Jafarpour, S., Ahsan, N., Mitchell, W. G., & Santoro, J. D. (2024) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2024.05.015 · Cited by 1
Personalized epigenetics of neurodegenerative diseases
Gautam, V., Sandhu, A., Rawat, K., Kumar, A., & Saha, L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23802-4.00020-x · Cited by 1
КЛИНИКО-ЭПИДЕМИОЛОГИЧЕСКАЯ ХАРАКТЕРИСТИКА И РЕЗУЛЬТАТЫ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
Quliyeva, A. İ. (2024) · Azerbajdžanskij medicinskij žurnal · doi:10.34921/amj.2024.37.98.001 · Cited by 1
Proteomics and Management of Multiple Sclerosis
Vo, A., Wong, K., Abram, A., Le, T. T. K., & Ho, L. (2024) · Springer eBooks · doi:10.1007/978-3-031-64021-6_11 · Cited by 1
COVID‐19 vaccination in patients with multiple sclerosis: what you need to know – a review
Mahmoudi, F., Mirmosayyeb, O., Shaabani, E., Ghaffary, E. M., & Nelson, F. M. (2024) · Health Science Reports · doi:10.1002/hsr2.70119 · Cited by 1
Beyond The Patient: Exploring The Psychological Burden On Caregivers Of Multiple Sclerosis Patients
Sarıkaya, C., & Efendi, H. (2024) · Acta Medica Nicomedia · doi:10.53446/actamednicomedia.1486624 · Cited by 1
Miri, M., Tahami, E., & Veisi, G. (2024) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2024.106193 · Cited by 1
Unexpected Convergence: A Case Report of Achalasia in a Patient With Multiple Sclerosis
Graham, S. S., Carrasco, A. E., Liu, J., Khalaf, M., & Leland, W. J. (2025) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2024.0580 · Cited by 1
Association Between Sun Exposure and Risk of Relapse in Pediatric-Onset Multiple Sclerosis
Chang, G. T., Sebastian, P., Virupakshaiah, A., Schoeps, V. A., Cherbuin, N., Casper, T. C., Gorman, M., Benson, L. A., Chitnis, T., Rensel, M. R., et al. (2025) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200375 · Cited by 1
Davanian, F., Adibi, I., Tajmirriahi, M., Monemian, M., Zojaji, Z., Montazerolghaem, A., Asadinia, M. A., Mirghaderi, S. M., Esfahani, S. A. N., Kazemi, M., et al. (2025) · Journal of Medical Signals & Sensors · doi:10.4103/jmss.jmss_55_24 · Cited by 1
Shojaie, A., Kamali, H., Nematollahi, M., Imani‐Goghary, Z., & Bagherian, B. (2025) · Behavioural Neurology · doi:10.1155/bn/9961468 · Cited by 1
“Multiple sclerosis (MS) is a chronic disorder of the central nervous system (CNS) with unknown etiology that is the most common cause of nontraumatic disability among young adults [1].”
Elsesy, E. H. E., Elsharkawy, R. E., & Osman, M. A. (2025) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-025-00962-9 · Cited by 1
“On the other hand, primary progressive MS (PPMS), observed in less than 10% of patients, is characterized by steady neurological deterioration from disease onset without distinct relapses [2].”
Acute disseminated encephalomyelitis - a monophonic illness
Singh, N. K., Gupta, V., & Mishra, S. K. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.04.004 · Cited by 1
Capper, E. N., Anders, J. J., Elwood, B. W., Kardon, R. H., & Gramlich, O. W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1587760 · Cited by 1
“To summarize, MS is a chronic neurodegenerative disease that is associated with ON and other long-lasting visual de fi cits (1, 4).”
InfluentialRobles-Sanchez, M.-A., Bujan, P. A., Bosch‐Farré, C., Coll, C., Arévalo, M. J., Anglada, E., Menéndez, R., Aroca-Alsina, M., Merchan-Ruiz, M., Pérez‐Hoyos, S., et al. (2025) · Revista Científica de la Sociedad Española de Enfermería Neurológica · doi:10.1016/j.sedene.2025.500192 · Cited by 1
Ashtari, F., Pirmoradian, M., Kavosh, A., Arabi, S., Adibi, I., Feizi, A., & Ghalamkari, A. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106590 · Cited by 1
Error evaluation and stability analysis of numerical schemes in multiple sclerosis modeling
Afzal, Z., & Alshehri, M. H. (2025) · Ain Shams Engineering Journal · doi:10.1016/j.asej.2025.103551 · Cited by 1
Fernández-Cuerva, C., Alarcón, A. L., Lara, M. J. M., Alonso, A., Reyes-Garrido, V., Urbaneja, P., & Benavente, A. S.-G. (2025) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2024-004378 · Cited by 1
Yang, C., Jiang, X., Cheng, Z., Zheng, C., & Hu, C. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578704 · Cited by 1
Liu, P.-J., Yuan, P., & Liu, S. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s519729 · Cited by 2
A comprehensive review of lines in ophthalmology – The posterior segment
Nayak, M., Sharma, H., Kalra, J., Jain, A., Virdiana, M., Rao, A., Ibrahim, S., & Kamath, Y. S. (2025) · Journal of Clinical Ophthalmology and Research · doi:10.4103/jcor.jcor_206_24 · Cited by 1
Administration of siponimod in real clinical practice in Russia
Davydovskaia, M. V., Arzumanyan, N. S., Александровна, Д. Е., Борисовна, С. В., Shumilina, M. V., Krivomlina, E. V., Gorshkova, L. Y., Sutormin, M. V., Sokolova, A. A., Bakhtiyarova, K. Z., et al. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-281 · Cited by 1
Role of isoflavones in multiple sclerosis
vardhini, V. A., Sowmiya, S., Sameer, S. A., Sakthi, R., Divya, R., & Monisha, A. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.08.012 · Cited by 1
“Multiple sclerosis (MS) is the leading cause of nontraumatic neurological impairment in young adults be-tween the ages of 20 and 40 (Hauser and Cree, 2020; Sospedra and Martin, 2005; Adamu et al., 2024).”
Li, C., Kang, J., Wang, X., Wang, L., & Li, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1643938 · Cited by 1
“Clinically, by using pharmacological treatments that modulate the immune system and reduce in fl ammation, to delay the progression of the disease and reduce the disability rate (11).”
Cropano, M., Lus, G., Gaita, M., Ammendola, L., Malangone, D., Signoriello, E., & Raimo, S. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08463-6 · Cited by 1
“Multiple Sclerosis (MS) is a chronic, progressive autoimmune disorder that primarily affects the central nervous system, leading to demyelination and subsequent neurodegeneration [1].”
Bordet, C., Maachi, O., Papeix, A.-C., Laigo, P., Thomas, L., & Grimaldi‐Bensouda, L. (2025) · Multiple Sclerosis Journal · doi:10.1177/13524585251377411 · Cited by 1
Innate Immunity in the Pathogenesis of Selected Autoimmune Neurological Diseases
Rudnicka-Czerwiec, J., & Bartosik-Psujek, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207235 · Cited by 1
“Currently approved and widely used DMTs predominantly target adaptive immunity, although they may indirectly influence innate immune pathways [145].”
Manrique-Samer, A., Cifuentes‐González, C., Álvarez-Martínez, J. V., Rojas-Carabali, W. A., Cortés-Albornoz, M. C., Vélez-van-Meerbeke, A., Salas, P. A. O., Vanegas, A. C., Guío‐Sánchez, C., Cardona-López, J., et al. (2025) · Neuro-Ophthalmology · doi:10.1080/01658107.2025.2563194 · Cited by 1
Liu, P.-J., Yuan, P., & Liu, S. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s540152 · Cited by 1
“Owing to the small number of patients in the progressive subgroups, the achieved power was very low (18.2% for PPMS; 11.6% for SPMS).”
InfluentialTranscription factor c-Maf: a checkpoint that programs autoimmunity
Liu, N., Zhang, J., Wang, P., Jin, S., Yang, C., Yan, X., Xu, J., Wang, H., Sun, W., & Xu, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1682098 · Cited by 1
“Multiple sclerosis (MS) is a chronic in fl ammatory disorder of the central nervous system (CNS) characterized by autoimmune-mediated demyelination (106).”
Peters, A., Yasuhara, K., Su, W., Matsumoto, S. G., Pham, P. T., Banine, F., Harris, E., Back, S. A., & Sherman, L. S. (2025) · ASN NEURO · doi:10.1080/17590914.2025.2600157 · Cited by 1
“Currently approved therapies for MS target the immune system to reduce the number of neuroinflammatory attacks, however demyelination still occurs and almost all patients experience disease progression (Hauser and Cree, 2020).”
Kolo, R. M., Ehirim, C. B., Olabiyi, D. O., Ayobamidele, I. A., Jaji‐Sulaimon, R., & Omotoso, G. O. (2025) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173251405050 · Cited by 1
Alnajashi, H. A., Almohammed, H. A., Morad, A. S., Saddiq, B. W. B., Kushara, K. F., Zoabi, B. M. K. A., Aldawsari, W. A., Almuhaysin, F. I., Gasim, M. A., Alharbi, H. A., et al. (2025) · BMC Neurology · doi:10.1186/s12883-025-04514-9 · Cited by 1
Managing reactivation of multiple sclerosis during treatment with natalizumab
Lizak, N., Sharmin, S., Horáková, D., Havrdová, E., Eichau, S., van der Walt, A., Butzkueven, H., Lechner‐Scott, J., Buzzard, K. A., Skibina, O. G., et al. (2025) · Multiple Sclerosis Journal · doi:10.1177/13524585251398682 · Cited by 1
“1 .”
Early determinants of long-term outcomes in multiple sclerosis
Dörtkol, O., Emekli, A. S., Hacılar, E., Erden, S. Ö., Gündüz, T., & Kürtüncü, M. (2026) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106964 · Cited by 1
Zhao, T., Ahmad, H., Ng, H. S., Laslett, L. L., van der Mei, I. A. F., Taylor, B. V., & Palmer, A. J. (2026) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2026.107011 · Cited by 1
Kim, N., Stuifbergen, A. M., Becker, H., Swift‐Scanlan, T., Osier, N. S., & Buxhoeveden, S. (2026) · Western Journal of Nursing Research · doi:10.1177/01939459251405618 · Cited by 1
Wyse, J. M., Nieto, M. P., Zhang, J., Hsu, C. G., & Wechsler, M. E. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70115 · Cited by 1
“13,14 The applications of targeting strategies to reduce ROS for MS patients could decrease the inflammation observed around the oligodendrocytes and thus allow for the possible restoration of the myelin sheath.”
Morozzi, M., Borgonetti, V., Sasia, C., Videtta, G., Calenda, S., Catarzi, D., Varano, F., Colotta, V., & Galeotti, N. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.110857 · Cited by 1
Pençeci, B., Üstündağ, C. B., & Çakır-Koç, R. (2026) · Macromolecular Bioscience · doi:10.1002/mabi.202500629 · Cited by 1
Therapeutic strategies in multiple sclerosis: a systematic review of current and emerging approaches
Machado, C., & Valado, A. (2026) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2026.1004138 · Cited by 1
Quasi-steady-state CEST for rapid and quantitative lesion detection in multiple sclerosis at 3T
Zhang, H., Wang, Z., Zeng, S., Wang, J., Cai, P., Mak, H. K. F., Chan, K. H., Qiu, B., & Huang, J. (2026) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2026.111774 · Cited by 1
The Role of Human Microbiota in Autoimmune Diseases: Exploring Dysbiosis and Mechanisms
Liu, S., Sanaie, S., Abdollahi, H., Yazdanfar, F., Khaki, S. N., kheiri, S. V., & Mobed, A. (2026) · Apmis · doi:10.1111/apm.70159 · Cited by 2
Türker, E., Kılıç, B., & Demirkaya, Ş. (2026) · Healthcare · doi:10.3390/healthcare14060743 · Cited by 1
“Despite the development of numerous treatment options to alter the course of MS, a cure that completely eliminates the disease has not yet been found [5].”
Jafari, M., Panah, M. Y., Vaheb, S., Adibi, I., Ashtari, F., Shaygannejad, V., Zabeti, A., & Mirmosayyeb, O. (2026) · Health Science Reports · doi:10.1002/hsr2.72142 · Cited by 1
“Although current therapies effectively reduce or prevent relapses in RRMS patients, they show limited efficacy in controlling relapse‐ independent progression and offer minimal benefit for PMS patients [3].”
Elshony, H., Almuhanna, R. A., Al-Ghamdi, A., Almatrafi, M. K., Ashshi, M. A., Almatani, M. U., Al-Ghamdi, T. S., Tawakul, A. A., Elsaadawy, R., & Muddassir, R. (2026) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-026-10288-9 · Cited by 1
Bartczak, J., Gronowski, P., Małek, M., Denkiewicz, A., Grodzka, O., Chądzyński, P. R., & Domitrz, I. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114104 · Cited by 1
“These agents effectively suppress clinical relapses and radiological activity while mitigating the risk of long-term disability progression [9].”
InfluentialPark, J., Kang, S., Kim, S., Kim, D., Shin, B., Mun, J. Y., Park, Y., Kim, J., Goldman, S. A., & Kim, K.-P. (2026) · Cells · doi:10.3390/cells15121067 · Cited by 1
“While current pharmacological interventions, primarily immunomodulators, are effective in retarding disease progression by suppressing inflammation, they fail to restore the loss of oligodendrocytes and myelin [10,11].”
Nimodipine in animal models of demyelination relevant to multiple sclerosis: a systematic review
Vakilipour, P., Sadigh‐Eteghad, S., Naseri, A., & Bonabi, M. A. (2026) · Brain Research · doi:10.1016/j.brainres.2026.150479 · Cited by 1
Artificial intelligence in biomarker discovery for diseases: diagnostic and therapeutic prospects
Dinç, R., & Ardıç, N. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02946-4 · Cited by 1
“225,226 Nevertheless, performance often remains sensitive to cohort composition, reference standards, and healthcare system-speci fi c factors.”
Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis
Ridley, B., Minozzi, S., González‐Lorenzo, M., Giovane, C. D., Filippini, G., Peryer, G., Foschi, M., Tramacere, I., Baldin, E., & Nonino, F. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015443 · Cited by 1
Neuroprotective effect of Vesatolimod in an experimental autoimmune encephalomyelitis mice model
Jiang, X., Song, Y., Fang, J., Yang, X., Mu, S., & Zhang, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109717 · Cited by 1
DAMPs in Organ-Specific Autoimmune Diseases
Land, W. G. (2023) · Springer eBooks · doi:10.1007/978-3-031-21776-0_8 · Cited by 1
Multiple Sclerosis: A Review with a Focus on the Middle East and North Africa Region
Zeineddine, M. M., Al‐Hajje, A., & Ismail, G. (2023) · Springer eBooks · doi:10.1007/978-3-030-74786-2_47-1 · Cited by 1
Reza, M., Cahill, J. F. X., Hungria, E. F., Stanton, L., Kritselis, M. A., Donahue, J. E., Sanborn, V. E., & Wu, C. (2023) · Advances in Psychiatry and Behavioral Health · doi:10.1016/j.ypsc.2023.04.001 · Cited by 1
Clinical cases on functional neurosurgery and motor speech disorders
Konstantopoulos, K., & Giakoumettis, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823875-2.00001-3 · Cited by 1
Gassama, S., Garmendia, A. M., Lejeune, F., de la Motte, M. B., Louapre, C., Papeix, C., Maillart, É., & Roux, T. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2023.03.028 · Cited by 1
Bünül, S. D. (2023) · BOĞAZİÇİ TIP DERGİSİ · doi:10.14744/bmj.2023.43265 · Cited by 1
“[7] 8-12] The World Health Organization defines treatment adherence as “the extent to which a person’s behavior-in terms of taking medications, following diets, and/or executing lifestyle changes-corresponds to the recommendations agreed on by a healthcare provider.””
BackgroundRegulation of Antigen‐Specific Immunotherapy with Nanomaterials
Ye, W., Jia, Y., Ren, H., Xie, Y., Yu, M., & Chen, Y. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300068 · Cited by 1
Binshalan, T., Buckley, E. E., Nair, S., & McNeill, A. (2024) · Cureus · doi:10.7759/cureus.51811 · Cited by 1
Lino, A. C., & Dörner, T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95895-0.00007-6 · Cited by 1
Ipavec, N., Vidaković, M. R., Markotić, A., Pavelin, S., Šoda, M. B., Šoda, J., Dolić, K., & Mužinić, N. R. (2024) · Biomedicines · doi:10.3390/biomedicines12020464 · Cited by 1
“It reduces the progression of clinical impairment by around 25% and improves both clinical and magnetic resonance imaging (MRI) indicators of inflammation and degeneration in PPMS [38].”
BackgroundESCLEROSE MÚLTIPLA - ABORDAGENS DIAGNÓSTICAS E TERAPÊUTICAS: UMA REVISÃO BIBLIOGRÁFICA
Bezerra, L. M. R., Yamashita, F. A., Pinho, J. L. L. F., Sobrinho, J., Rocha, C. C. S., Pires, C. B. R., Urzedo, G. O. Q., & Silva, C. D. M. (2024) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v5i2.4950 · Cited by 1
Cell Membrane Surface-Engineered Nanoparticles for Autoimmune Diseases and Immunotherapy
Khademi, Z., Falsafi, M., Taghdisi, S. M., & Abnous, K. (2024) · ACS symposium series · doi:10.1021/bk-2024-1464.ch010 · Cited by 1
Osteoporosis in a Woman With Multiple Sclerosis: A Case Report
Kostoglou‐Athanassiou, I., Athanassiou, L., Athanassiou, P., Giannakopoulos, A., & Shoenfeld, Y. (2024) · Cureus · doi:10.7759/cureus.59287 · Cited by 2
“Multiple sclerosis is treated with immunomodulatory agents [5], including corticosteroids, which may affect bone metabolism [6].”
BackgroundSgroi, S., Romeo, E., Albanesi, E., Piccardi, F., Catalano, F., Debellis, D., Bertozzi, F., & Reggiani, A. M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116677 · Cited by 1
A. millefolium L. in pharmacy. What should a pharmacist know?
Ancuceanu, R., Hovaneț, M. V., Anghel, A.-I., & Dinu, M. (2023) · Romanian Journal of Pharmaceutical Practice · doi:10.37897/rjphp.2023.3-4.4 · Cited by 1
“The authors claimed a faster recovery for the intervention group versus the controlled group (mean 1.31 days vs. 1.86 days, p = 0.015) [37].”
BackgroundInfluentialMycko, M. P. (2023) · Aktualności Neurologiczne · doi:10.15557/an.2023.0012 · Cited by 1
NEUROFILAMENTS AS A POTENTIAL BIOMARKER IN PATIENTS WITH MULTIPLE SCLEROSIS: A REVIEW OF LITERATURE
Yanakieva, M., Danovska, M., Ovcharova, E. M., & Marinova, D. L. (2024) · Journal of IMAB - Annual Proceeding (Scientific Papers) · doi:10.5272/jimab.2024302.5527 · Cited by 1
Self-care Training Program for Patients Suffering from Multiple Sclerosis
Hassan, G. S., Ahmed, F. H., Mohamed, W. A.-K., & Elsheshiny, A. H. (2024) · Egyptian Journal of Health Care · doi:10.21608/ejhc.2024.356284 · Cited by 1
Banasadegh, S., Shahrbanian, S., Gharakhanlou, R., Kordi, M. R., & Soltani, B. M. (2024) · Journal of Ethnicity in Substance Abuse · doi:10.1080/15332640.2024.2365230 · Cited by 1
“At first, physical exercise was thought to be harmful for patients with MS; But it is included in current treatment guidelines (Hauser & Cree, 2020; Mandolesi et al., 2018; Motl et al., 2017).”
Nanocarriers and Nano Drug Delivery Therapy in Neuro Diseases
Rana, P., Kaur, G., Chirayimmel, A. J., Rajput, A., Rath, S. K., & Dwibedi, V. (2024) · Smart nanomaterials technology · doi:10.1007/978-981-97-0308-1_10 · Cited by 1
Evaluation of Salivary Thiol-Disulphide Homeostasis in Multiple Sclerosis Patients
Kırzıoğlu, F. Y., Demirci, S., Varol, Ç., Ünlü, M. D., Calapoğlu, M., & Orhan, H. (2024) · SDÜ Tıp Fakültesi Dergisi · doi:10.17343/sdutfd.1329050 · Cited by 1
Projected number of people with multiple sclerosis in Germany between 2015 and 2040
Baginski, K., Voeltz, D., & Hoyer, A. (2024) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2024.105774 · Cited by 1
Lopes, P. L., da Costa, F. B. S., Braga‐Neto, P., Sobreira-Neto, M. A., Júnior, A. M. D., & Nóbrega, P. R. (2024) · Revista de Medicina da UFC · doi:10.20513/2447-6595.2024v64n1e83250
“19,23 We also report 7 cases of COVID-19 after vaccination, all mild cases.”
BackgroundSystematic review on Ocrevus for treatment of multiple sclerosis
Subuhan, S. M. S. A., & W.Helen (2024) · World Journal of Biology Pharmacy and Health Sciences · doi:10.30574/wjbphs.2024.19.1.0468 · Cited by 1
Progressive multiple sclerosis: A bibliometric analysis
Shawawrah, M. A. K., & AlRyalat, S. A. (2024) · Medicine · doi:10.1097/md.0000000000039034 · Cited by 1
Özbaş, E., Balkan, A. F., & Salcı, Y. (2024) · Acta Neurologica Belgica · doi:10.1007/s13760-024-02673-z · Cited by 1
“The disease is character - ized by a broad range of neurological signs and symptoms, primarily attributed to extensive lesions in the CNS, leading to visual, bulbar, sensory, motor, and cognitive impairments [2, 3].”
Uçar, S., Sürmelioğlu, Ö., & Dana, H. (2024) · Meandros Medical And Dental Journal · doi:10.69601/meandrosmdj.1558551 · Cited by 1
Surveillance of drug prescribing: why outliers miss their targets – a qualitative study
Gollnick, J., Zeschick, N., Hörbrand, F., Killian, P., Sebastião, M., Kühlein, T., & Donner‐Banzhoff, N. (2025) · BMC Health Services Research · doi:10.1186/s12913-024-12189-0 · Cited by 1
Khedr, E. M., Fawal, B. M. A., Gamal, R., Saber, M., & Shoeb, A. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106336 · Cited by 1
Hladkykh, F., Liadova, T., & Matvieienko, М. S. (2024) · Psychiatry Neurology and Medical Psychology · doi:10.26565/2312-5675-2024-26-02 · Cited by 1
Disanto, G., Schädelin, S., Oechtering, J., Lorscheider, J., Galbusera, R., Finkener, S., Achtnichts, L., Lalive, P. H., Müller, S., Pot, C., et al. (2025) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173251315457 · Cited by 1
Guazzo, A., Longato, E., Trescato, I., Tavazzi, E., Chiò, A., Manera, U., Zocco, G., Cavalla, P., Vercellino, M., Ahmad, L., et al. (2025) · Lecture notes in computer science · doi:10.1007/978-3-031-82484-5_4 · Cited by 1
Polistena, B., Provenzano, A. M., Rizzi, C., Colombo, E., & Bergamaschi, R. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00761-7 · Cited by 1
“These drugs are classically divided into two groups: first-line therapies and high-efficacy therapies (HET) [7].”
Adherence to therapeutic recommendation in relapsing-remitting multiple sclerosis patients
Chojdak-Łukasiewicz, J., Kołtuniuk, A., Sawicka, E., & Pokryszko‐Dragan, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1545430 · Cited by 1
López-Caneda, C. H., Antón-Fuente, S., Pérez-Haro, M. J., Sánchez-Franco, C. M., Álvarez, E., Aguado-Valcárcel, M., Marcos-Bobillo, M., Torrente-Carballido, M., & González‐Suarez, I. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00811-0 · Cited by 1
Almarhoon, F. H., & Almubarak, A. (2021) · International Journal of Medicine in Developing Countries · doi:10.24911/ijmdc.51-1609661004 · Cited by 1
Multiple sclerosis patients and e-health system in Saudi Arabia
Alshamrani, F., & Alnajashi, H. A. (2021) · International Journal of Human Rights in Healthcare · doi:10.1108/ijhrh-01-2021-0007 · Cited by 1
Retracted
Metadata
- Authors
- Hauser, S. L., & Cree, B. A. C.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Hauser, Stephen L.
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 133
- Issue
- 12
- Pages
- 1380-1390.e2
- ISSN
- 0002-9343 (ISSN-L)
- PMC
- PMC7704606
- OpenAlex
- W3042308502
- Cited by
- 969
- References
- 81
- Citations by year
- 2026: 149 · 2025: 208 · 2024: 229 · 2023: 175 · 2022: 135 · 2021: 64 · 2020: 7
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The American Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Novartis
- Roche
- National Institute of Neurological Disorders and Stroke (R35NS111644)
- TG Therapeutics
- Valhalla Foundation
- National Multiple Sclerosis Society (RR 2005-A-13)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- multiple sclerosis, relapsing-remitting multiple sclerosis, disease-modifying therapy, B-cell therapy, T cell-mediated autoimmunity, neurodegeneration, disability progression, symptom management, first-line therapy, long-term prognosis
- MeSH terms
- Antibodies, Monoclonal, Humans, Immunosuppressive Agents, Multiple Sclerosis, Physical Therapy Modalities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
